Patents Assigned to Pharmacosmos Holding A/S
-
Patent number: 11851504Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.Type: GrantFiled: January 6, 2021Date of Patent: December 26, 2023Assignee: PHARMACOSMOS HOLDING A/SInventor: Hans Andreasen
-
Patent number: 11806329Abstract: The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.Type: GrantFiled: March 1, 2021Date of Patent: November 7, 2023Assignee: PHARMACOSMOS HOLDING A/SInventors: Tobias Sidelmann Christensen, Philip Schaffalitzky De Muckadell, Lars Lykke Thomsen, Claes Christian Strom
-
Patent number: 11633489Abstract: Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.Type: GrantFiled: February 18, 2021Date of Patent: April 25, 2023Assignee: PHARMACOSMOS HOLDING A/SInventors: Lars Lykke Thomsen, Tobias S. Christensen, Hans Andreasen
-
Patent number: 11484025Abstract: The present invention relates to a cryoprotecting agent comprising a cryprotectant being one or more of: dextrin, dextran, isomaltooligosaccharide and derivatives thereof, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation.Type: GrantFiled: November 29, 2013Date of Patent: November 1, 2022Assignee: PHARMACOSMOS HOLDING A/SInventors: Hans Berg Andreasen, Lars Christensen, Kim Nordfjeld, Jeppe Skytte, Christian Clausen, Bjorn Holst
-
Patent number: 11471483Abstract: The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, or pallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.Type: GrantFiled: February 23, 2021Date of Patent: October 18, 2022Assignee: PHARMACOSMOS HOLDING A/SInventors: Lars Lykke Thomsen, Tobias S. Christensen, Hans Andreasen
-
Patent number: 11111261Abstract: The present invention relates to iron complex compounds for therapeutic use which are low in arsenic, chromium, lead, cadmium, mercury and/or aluminum, compositions thereof and processes for preparing said iron complex compounds.Type: GrantFiled: February 13, 2019Date of Patent: September 7, 2021Assignee: Pharmacosmos Holding A/SInventors: Tobias S. Christensen, Hans B. Andreasen
-
Patent number: 11040059Abstract: The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.Type: GrantFiled: October 27, 2015Date of Patent: June 22, 2021Assignee: Pharmacosmos Holding A/SInventors: Christian von der Recke, Tobias S. Christensen, Hans Andreasen, Lars Lykke Thomsen
-
Patent number: 11040064Abstract: The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, orpallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.Type: GrantFiled: March 17, 2016Date of Patent: June 22, 2021Assignee: Pharmacosmos Holding A/SInventors: Lars Lykke Thomsen, Tobias S. Christensen, Hans Andreasen
-
Patent number: 11020369Abstract: The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.Type: GrantFiled: March 18, 2020Date of Patent: June 1, 2021Assignee: PHARMACOSMOS HOLDING A/SInventors: Tobias Sidelmann Christensen, Philip Schaffalitzky De Muckadell, Lars Lykke Thomsen, Claes Christian Strom
-
Patent number: 10960081Abstract: Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.Type: GrantFiled: June 22, 2016Date of Patent: March 30, 2021Assignee: PHARMACOSMOS HOLDING A/SInventors: Lars Lykke Thomsen, Tobias S. Christensen, Hans Andreasen
-
Patent number: 10865255Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.Type: GrantFiled: July 28, 2016Date of Patent: December 15, 2020Assignee: Pharmacosmos Holding A/SInventor: Hans Andreasen
-
Patent number: 10414831Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.Type: GrantFiled: November 2, 2018Date of Patent: September 17, 2019Assignee: PHARMACOSMOS HOLDING A/SInventor: Hans Andreasen
-
Publication number: 20180133335Abstract: Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.Type: ApplicationFiled: June 22, 2016Publication date: May 17, 2018Applicant: Pharmacosmos Holding A/SInventors: Lars Lykke THOMSEN, Tobias S. CHRISTENSEN, Hans ANDREASEN
-
Publication number: 20180042960Abstract: The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, orpallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.Type: ApplicationFiled: March 17, 2016Publication date: February 15, 2018Applicant: Pharmacosmos Holding A/SInventors: Lars Lykke THOMSEN, Tobias S. CHRISTENSEN, Hans ANDREASEN
-
Publication number: 20170333470Abstract: The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.Type: ApplicationFiled: October 27, 2015Publication date: November 23, 2017Applicant: Pharmacosmos Holding A/SInventors: Christian von der RECKE, Tobias S. CHRISTENSEN, Hans ANDREASEN, Lars Lykke THOMSEN
-
Publication number: 20160333118Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.Type: ApplicationFiled: July 28, 2016Publication date: November 17, 2016Applicant: Pharmacosmos Holding A/SInventor: Hans ANDREASEN
-
Patent number: 9439969Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.Type: GrantFiled: June 18, 2014Date of Patent: September 13, 2016Assignee: Pharmacosmos Holding A/SInventor: Hans Andreasen
-
Patent number: 8815301Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.Type: GrantFiled: March 25, 2009Date of Patent: August 26, 2014Assignee: Pharmacosmos Holding A/SInventor: Hans Andreasen
-
Publication number: 20120010166Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.Type: ApplicationFiled: March 25, 2009Publication date: January 12, 2012Applicant: Pharmacosmos Holding A/SInventor: Hans Andreasen
-
Patent number: 6977249Abstract: In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average molecular weight of the resulting iron-dextran compound can be varied.Type: GrantFiled: July 29, 1999Date of Patent: December 20, 2005Assignee: Pharmacosmos Holding A/SInventors: Hans Berg Andreasen, Lars Christensen